This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed.
I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief into making the Ocumetics Lens a reality. To now see it safely implanted and beginning to change lives is remarkable. These are the moments we dreamed of.
The early signs are encouraging and give us confidence as we move forward with the next surgical day and complete the first group of patients. The real test lies ahead, as healing continues and vision outcomes begin to emerge.
This achievement is proof that bold ideas, relentless effort, and true teamwork can change the world. And make no mistake—we are changing the world.
Thank you for believing. Thank you for persevering. And thank you for standing shoulder to shoulder with us on this journey. Together, we are making history.
With pride and gratitude,
Dean Burns
President, CEO and Director
Ocumetics Technology
Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire – May 12, 2026
Calgary, Alberta – TheNewswire – April 29, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to
Key Highlights Vision performance: Clinical outcomes exceed expectations, with all patients experiencing continuing vision improvements Safety profile: Continues to meet expectations Quality-of-life improvements: Anecdotally, all patients reported life changing results from lens implantations Technology validation: Results reinforce the expected performance of Ocumetics’ inaugural accommodating intraocular lens Momentum: Forward momentum continues, with lens design enhancements
Key Highlights No material change: There is no material change in the business affairs of Ocumetics. Attendance at ASCRS: Productive ASCRS meetings with major global ophthalmic leaders. Clinical and development momentum: Feedback supported positive results from the First-in-Human (FIH) Group 1 study while the Company advances toward Group 2 patient recruitment and upcoming surgeries. Regulatory
